Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA       ES0171996012

GRIFOLS SA
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 4 354 M
EBIT 2017 1 093 M
Net income 2017 598 M
Debt 2017 5 558 M
Yield 2017 1,35%
Sales 2018 4 543 M
EBIT 2018 1 176 M
Net income 2018 680 M
Debt 2018 5 186 M
Yield 2018 1,52%
P/E ratio 2017 29,59
P/E ratio 2018 25,69
EV / Sales2017 5,02x
EV / Sales2018 4,73x
Capitalization 16 291 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
Sector
Pharmaceuticals
Calendar
03/01Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
01/02 GRIFOLS : Frederick plasma center creates little free library for community
2017 QORVO : Duke Energy announces 2017 Power Partner award winners
2017 U.S. tax cuts mix pleasure and pain for Europe's dollar earners
2017 GRIFOLS : and the European Investment Bank sign an Euros 85 million long-term lo..
2017 GRIFOLS : Misterium Cleanroom Solutions Expands to Include Revolutionary Deconta..
2017 GRIFOLS : EIB, Grifols Sign New Loan Agreement to Support Research on Rare, Chro..
2017 GRIFOLS : The EIB and Grifols sign a new loan agreement to support research on r..
2017 GRIFOLS : and the European Investment Bank sign an Euros 85 million long-term lo..
2017 GRIFOLS : and the European Investment Bank sign an Euros 85 million long-term lo..
2017 GRIFOLS SA : ex-dividend day for interim dividend
More news
Sector news : Biopharmaceuticals
01:38p ABLYNX : Largest Ablynx investor would consider improved Novo Nordisk bid
12:27p BTG : U.S. court invalidates Johnson & Johnson cancer drug patent, hitting UK's ..
01/17 TSX ends up as banks lead rally after rate hike
01/17 ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
01/17 EXCLUSIVE : J&J attracts Chinese interest for diabetes business in potential $3-..
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 23
Average target price 25,4 €
Spread / Average Target -2,5%
EPS Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Víctor Grifols Roura Non-Executive Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Vicente Blanquer Torre Vice President-Quality, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA20 235
BIOGEN6.37%71 659
CSL LIMITED0.51%51 198
ALEXION PHARMACEUTICALS4.09%27 810
GRIFOLS SA6.73%20 235
BIOMARIN PHARMACEUTICAL1.20%15 848